NIH Weekly Funding Opportunities and Policy Notices
Funding Opportunity PA-18-573 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA), issued by the National Institutes of Health (NIH), the Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA), invites eligible United States small business concerns (SBCs) to submit Small Business Innovation Research (SBIR) grant applications. United States SBCs that have the research capabilities and technological expertise to contribute to the R and D mission(s) of the NIH, CDC, and FDA awarding components identified in this FOA are encouraged to submit SBIR grant applications in response to identified topics (see PHS 2018-2 SBIR/STTR Program Descriptions and Research Topics for NIH, CDC, and FDA. This Parent Funding Opportunity Announcement requires that at least 1 clinical trial be proposed. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) or Agency based on their scientific missions.
Notice NOT-HL-18-580 from the NIH Guide for Grants and Contracts
Funding Opportunity PAR-18-580 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for disorders that fall under the mission of NIAAA. An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required.
Funding Opportunity PAR-18-578 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for disorders that fall under the mission of NIAAA. An identified candidate, having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application, is required prior to application. The FOA supports Investigational New Drug (IND)-enabling studies for the therapeutic candidate. At the end of the funding period, a successful project should have, at a minimum, an IND application submitted to the U.S. Food and Drug Administration (FDA). The program supports early-phase clinical trials, although these are not required.
Notice NOT-NS-18-036 from the NIH Guide for Grants and Contracts
Notice of Expiration of PAR-16-447 " NIAMS Clinical Trial Implementation Cooperative Agreement (U01)
Notice NOT-AR-18-014 from the NIH Guide for Grants and Contracts
African Association for Health Professions Education and Research (R25)(Clinical Trials Not Allowed)
Funding Opportunity RFA-TW-18-001 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this Fogarty International Center R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs by supporting the establishment of an African Association for Health Professions Education and Research (the "Association"). The Association will serve as a leadership and convening organization to network institutions across sub-Saharan Africa in order to jointly develop, disseminate, and share best practices, innovations, curricula, and policy and to engage in joint activities that will increase the quantity, quality and retention of African health professionals to address the crisis in HIV/AIDS and its' comorbidities on the continent. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on one or more of the following: Courses for Skills Development, Research Experiences, Mentoring Activities, Curriculum or Methods Development, and Outreach to broad communities and multiple stakeholders.
Notice NOT-HL-18-579 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-FD-18-004 from the NIH Guide for Grants and Contracts. The intended goal of this FOA is to facilitate the development, production, and distribution of pediatric medical devices. Although the FOA is issued by the FDA's Office of Orphan Products Development, the grant application is intended to encompass devices for all pediatric diseases and conditions, not just those that are rare. Applicants will request funding to serve as a nonprofit consortium to provide expert advising and support services to innovators of pediatric medical devices. The advising and services will focus on the total product life cycle for medical devices from concept, through pre-market development, to commercialization, and replacement by subsequent generation of devices. In addition, consortia should also provide expertise on evidence generation, including use of real world evidence, for pediatric device development. The pediatric population (i.e., neonates, infants, children, and adolescents) for medical devices is defined as individuals who are younger than 22 years of age (that is, from birth through the twenty-first year of life not including the twenty-second birthday) at the time of diagnosis or treatment.
Notice NOT-GM-18-014 from the NIH Guide for Grants and Contracts
Notice NOT-NS-18-034 from the NIH Guide for Grants and Contracts
Notice NOT-AI-18-009 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-573 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-574 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-575 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-576 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-577 from the NIH Guide for Grants and Contracts
Notice NOT-HL-18-578 from the NIH Guide for Grants and Contracts
Notice NOT-OD-18-126 from the NIH Guide for Grants and Contracts
Notice NOT-HL-17-572 from the NIH Guide for Grants and Contracts